Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies

PURPOSE: Parallel activation of the phosphatidylinositol 3-kinase–mammalian target of rapamycin pathway represents a mechanism of primary and acquired resistance to BRAF-targeted therapy, but the two pathways have yet to be cotargeted in humans. We performed a phase I study to evaluate the safety an...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JCO Precis Oncol
Autors principals: Subbiah, Vivek, Sen, Shiraj, Hess, Kenneth R., Janku, Filip, Hong, David S., Khatua, Soumen, Karp, Daniel D., Munoz, Javier, Falchook, Gerald S., Groisberg, Roman, Tsimberidou, Apostolia M., Sherman, Steven I., Hwu, Patrick, Meric-Bernstam, Funda
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2018
Matèries:
Original Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7446411/
https://ncbi.nlm.nih.gov/pubmed/32913986
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.18.00189
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars